Nongnuch Sirachainan1, Atthaporn Boongird2, Thiti Swangsilpa3, Wipawi Klaisuban4, Apasri Lusawat5, Suradej Hongeng6. 1. Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, 10400, Thailand. 2. Department of Surgery, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, 10400, Thailand. 3. Department of Radiology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, 10400, Thailand. 4. Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, 10400, Thailand. 5. Department of Pediatric Neurology, Prasat Neurological Institute, Department of Medical Services, Ministry of Public Health, Bangkok, 10400, Thailand. 6. Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, 10400, Thailand. suradej.hon@mahidol.ac.th.
Abstract
PURPOSE: The outcome of children with high-grade gliomas (HGGs) treated with radiation and adjuvant chemotherapy remains poor. The expression of epidermal growth factor receptor (EGFR) has been established in children with HGGs. This report demonstrated the outcomes of adjuvant nimotuzumab, an EGFR inhibitor, with irinotecan in pediatric HGGs. METHODS: Children with newly diagnosed HGGs were enrolled. Two weeks after surgery, nimotuzumab with a dose of 150 mg/m2 was given every week during radiation. After completion of radiation, a 4-week cycle of nimotuzumab (150 mg/m2) at week 1 and 3 and irinotecan (125 mg/m2) at week 1, 2, and 3 was given. RESULTS: Sixteen patients (5 females, 11 males), with a mean ± SD age of 8.2 ± 3.5 years were included. Tumors were located at the supratentorial region (50.0%), infratentorial region (43.8%), and both locations (6.2%). The 5-year PFS and OS were 19.9 ± 11.6 and 31.5 ± 13.0%, respectively. Median times of PFS and OS were 1.8 and 1.9 years, respectively. Prognostic factors related to good outcome were the location of tumor at the supratentorial region or outside brainstem and the extension of surgery. Side effects were minimal, with grade 1 anemia in three patients and diarrhea in one patient. Although, the adjuvant regimen of nimotuzumab and irinotecan slightly increases the overall outcome when compared to the historical study, the advantages of this protocol were minimal side effect, short period of hospitalization, and improved OS in patients who received extensive surgery.
PURPOSE: The outcome of children with high-grade gliomas (HGGs) treated with radiation and adjuvant chemotherapy remains poor. The expression of epidermal growth factor receptor (EGFR) has been established in children with HGGs. This report demonstrated the outcomes of adjuvant nimotuzumab, an EGFR inhibitor, with irinotecan in pediatric HGGs. METHODS:Children with newly diagnosed HGGs were enrolled. Two weeks after surgery, nimotuzumab with a dose of 150 mg/m2 was given every week during radiation. After completion of radiation, a 4-week cycle of nimotuzumab (150 mg/m2) at week 1 and 3 and irinotecan (125 mg/m2) at week 1, 2, and 3 was given. RESULTS: Sixteen patients (5 females, 11 males), with a mean ± SD age of 8.2 ± 3.5 years were included. Tumors were located at the supratentorial region (50.0%), infratentorial region (43.8%), and both locations (6.2%). The 5-year PFS and OS were 19.9 ± 11.6 and 31.5 ± 13.0%, respectively. Median times of PFS and OS were 1.8 and 1.9 years, respectively. Prognostic factors related to good outcome were the location of tumor at the supratentorial region or outside brainstem and the extension of surgery. Side effects were minimal, with grade 1 anemia in three patients and diarrhea in one patient. Although, the adjuvant regimen of nimotuzumab and irinotecan slightly increases the overall outcome when compared to the historical study, the advantages of this protocol were minimal side effect, short period of hospitalization, and improved OS in patients who received extensive surgery.
Authors: H S Friedman; W P Petros; A H Friedman; L J Schaaf; T Kerby; J Lawyer; M Parry; P J Houghton; S Lovell; K Rasheed; T Cloughsey; E S Stewart; O M Colvin; J M Provenzale; R E McLendon; D D Bigner; I Cokgor; M Haglund; J Rich; D Ashley; J Malczyn; G L Elfring; L L Miller Journal: J Clin Oncol Date: 1999-05 Impact factor: 44.544
Authors: Timothy F Cloughesy; Emese Filka; John Kuhn; Gillian Nelson; Fairooz Kabbinavar; Henry Friedman; Langdon L Miller; Gary L Elfring Journal: Cancer Date: 2003-05-01 Impact factor: 6.860
Authors: R Sposto; I J Ertel; R D Jenkin; C P Boesel; J L Venes; J A Ortega; A E Evans; W Wara; D Hammond Journal: J Neurooncol Date: 1989-07 Impact factor: 4.130
Authors: Johannes E A Wolff; Pablo Hernaiz Driever; Bernhard Erdlenbruch; Rolf D Kortmann; Stefan Rutkowski; Torsten Pietsch; Crystal Parker; Monica Warmuth Metz; Astrid Gnekow; Christof M Kramm Journal: Cancer Date: 2010-02-01 Impact factor: 6.860
Authors: Michael D Prados; Kathleen Lamborn; W K A Yung; Kurt Jaeckle; H Ian Robins; Minesh Mehta; Howard A Fine; Patrick Y Wen; Timothy Cloughesy; Susan Chang; M Kelly Nicholas; David Schiff; Harry Greenberg; Larry Junck; Karen Fink; Ken Hess; John Kuhn Journal: Neuro Oncol Date: 2006-03-13 Impact factor: 12.300
Authors: Marta Santisteban; Jan C Buckner; Joel M Reid; Wenting Wu; Bernd W Scheithauer; Matthew M Ames; Sara J Felten; Daniel A Nikcevich; Martin Wiesenfeld; Kurt A Jaeckle; Evanthia Galanis Journal: J Neurooncol Date: 2008-12-10 Impact factor: 4.130
Authors: Muhammad A Parenrengi; Wihasto Suryaningtyas; Asra Al Fauzi; Abdul Hafid Bajamal; Kurnia Kusumastuti; Budi Utomo; Ahmad Muslim Hidayat Thamrin; Bagus Sulistiono Journal: Cancer Control Date: 2022 Jan-Dec Impact factor: 3.302
Authors: Rami Hatoum; Jia-Shu Chen; Pascal Lavergne; Nathan A Shlobin; Andrew Wang; Lior M Elkaim; Philippe Dodin; Charles P Couturier; George M Ibrahim; Aria Fallah; Dominic Venne; Sebastien Perreault; Anthony C Wang; Nada Jabado; Roy W R Dudley; Alexander G Weil Journal: JAMA Netw Open Date: 2022-08-01